Albert David Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2026, recommended Final Dividend of Rs. 5 per equity share.
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts less than Nifty Microcap 250 and 9.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Albert David Limited's Board meeting on May 12, 2026 approved several key items. Mr. Amit Mahla was appointed as CEO, filling a vacancy left by Mr. Umesh Manohar Kunte's resignation from Managing Director & CEO position effective December 18, 2025. The company reported audited FY2026 results showing revenue of Rs. 33,359.81 Lakhs, a significant decline from Rs. 34,576.80 Lakhs in FY2025, with the company posting a loss of Rs. 149.47 Lakhs compared to a profit of Rs. 1,720.08 Lakhs in the previous year. The Board recommended a final dividend of Rs. 5 per equity share (50% of face value) for FY2026, subject to shareholder approval at the 87th AGM scheduled for August 6, 2026. Statutory auditors L.B. Jha & Co. issued an unmodified opinion on the financial results. PwC Services LLP and S. Gupta & Co. were re-appointed as internal and cost auditors respectively for FY2026-27.
The appointment of a new CEO with extensive pharma experience may provide positive sentiment, but weak financial performance with a net loss for FY2026 could weigh on investor confidence. The dividend recommendation provides some shareholder value support.